Straits Times Index
3,359.58 -28.94 (-0.85%) Nikkei
27,516.71 -89.75 (-0.33%) Hang Seng
21,344.88 +61.36 (+0.29%) FTSE 100
7,885.17 +20.46 (+0.26%) BTC-USD
22,477.95 -799.98 (-3.44%) CMC Crypto 200
517.51 -19.38 (-3.61%)
GILD May 2023 80.000 call
| Previous close | 8.55 |
| Open | 8.10 |
| Bid | 7.80 |
| Ask | 8.00 |
| Strike | 80.00 |
| Expiry date | 2023-05-19 |
| Day's range | 8.10 - 8.11 |
| Contract range | N/A |
| Volume | |
| Open interest | 486 |
- Zacks
Gilead's (GILD) Breast Cancer Drug Trodelvy Gets FDA Nod
Gilead Sciences, Inc. (GILD) announces the FDA approval of their first-in-class, Trop-2 directed antibody-drug conjugate, Trodelvy, for the treatment of metastatic HR+/HER2- breast cancer in adult patients.
- Motley Fool
Is Gilead Sciences a Good Stock to Buy Now?
Shares of Gilead Sciences (NASDAQ: GILD) marched higher on Thursday, Feb. 2 in response to a fourth-quarter earnings report that exceeded expectations. A day later, the U.S. Food and Drug Administration (FDA) agreed to dramatically increase the addressable patient population for an important cancer drug called Trodelvy. Gilead Sciences splashed out with a $21 billion acquisition of Immunomedics in 2020 for access to Trodelvy.
- Zacks
Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology
Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.
